MA51554A - Anticorps il-6 améliorés - Google Patents
Anticorps il-6 améliorésInfo
- Publication number
- MA51554A MA51554A MA051554A MA51554A MA51554A MA 51554 A MA51554 A MA 51554A MA 051554 A MA051554 A MA 051554A MA 51554 A MA51554 A MA 51554A MA 51554 A MA51554 A MA 51554A
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- improved
- Prior art date
Links
- 108090001005 Interleukin-6 Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C07K16/248—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462077105P | 2014-11-07 | 2014-11-07 | |
| US201462087448P | 2014-12-04 | 2014-12-04 | |
| US201562247705P | 2015-10-28 | 2015-10-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA51554A true MA51554A (fr) | 2020-11-18 |
Family
ID=54602042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA051554A MA51554A (fr) | 2014-11-07 | 2015-11-06 | Anticorps il-6 améliorés |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US11142571B2 (fr) |
| EP (3) | EP3632931A1 (fr) |
| JP (1) | JP6594438B2 (fr) |
| KR (2) | KR102636726B1 (fr) |
| CN (1) | CN107249631B (fr) |
| AU (1) | AU2015342882B2 (fr) |
| BR (1) | BR112017008672A2 (fr) |
| CA (1) | CA2965689C (fr) |
| CL (1) | CL2017001135A1 (fr) |
| CO (1) | CO2017005404A2 (fr) |
| CR (1) | CR20170231A (fr) |
| DK (1) | DK3215530T3 (fr) |
| EA (1) | EA035199B1 (fr) |
| ES (1) | ES2756275T3 (fr) |
| HK (1) | HK1244008A1 (fr) |
| HR (1) | HRP20191945T1 (fr) |
| HU (1) | HUE046181T2 (fr) |
| IL (1) | IL251858B (fr) |
| MA (1) | MA51554A (fr) |
| MX (2) | MX2017005992A (fr) |
| MY (1) | MY185114A (fr) |
| NZ (1) | NZ731090A (fr) |
| PE (1) | PE20171107A1 (fr) |
| PH (1) | PH12017500809A1 (fr) |
| PL (1) | PL3215530T3 (fr) |
| PT (1) | PT3215530T (fr) |
| RS (1) | RS59805B1 (fr) |
| SA (1) | SA517381458B1 (fr) |
| SG (2) | SG10202103420PA (fr) |
| SI (1) | SI3215530T1 (fr) |
| UA (1) | UA122673C2 (fr) |
| WO (1) | WO2016073890A1 (fr) |
| ZA (1) | ZA201702985B (fr) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA42924A (fr) | 2015-09-23 | 2018-08-01 | Hoffmann La Roche | Variants optimisés d'anticorps anti-vegf |
| JP2019510078A (ja) * | 2016-02-23 | 2019-04-11 | セセン バイオ， インコーポレイテッド | Ｉｌ−６アンタゴニスト製剤およびその使用 |
| MX2019007144A (es) * | 2016-12-19 | 2019-10-07 | Glenmark Pharmaceuticals Sa | Nuevos agonistas de tnfr y sus usos. |
| SG11201908650PA (en) | 2017-03-22 | 2019-10-30 | Genentech Inc | Optimized antibody compositions for treatment of ocular disorders |
| SG10202107829YA (en) | 2017-03-22 | 2021-08-30 | Genentech Inc | Hydrogel cross-linked hyaluronic acid prodrug compositions and methods |
| CN109867723B (zh) * | 2017-12-05 | 2022-06-17 | 南京金斯瑞生物科技有限公司 | 抗人il6单克隆抗体及其制备方法和用途 |
| JP2023517345A (ja) | 2020-03-13 | 2023-04-25 | ジェネンテック， インコーポレイテッド | 抗インターロイキン－３３抗体及びその使用 |
| WO2021194913A1 (fr) | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Agents de liaison à tie2 et leurs procédés d'utilisation |
| AU2021361108A1 (en) | 2020-10-15 | 2023-05-25 | F. Hoffmann-La Roche Ag | Non-covalent protein-hyaluronan conjugates for long-acting ocular delivery |
| CN114525235B (zh) * | 2022-02-25 | 2023-07-14 | 郑州大学 | 一种提高人表皮生长因子分泌生产效率的方法 |
| WO2024088921A1 (fr) * | 2022-10-24 | 2024-05-02 | F. Hoffmann-La Roche Ag | Prédiction de réponse à des antagonistes d'il-6 |
Family Cites Families (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4548990A (en) | 1983-08-15 | 1985-10-22 | Ciba-Geigy Corporation | Crosslinked, porous polymers for controlled drug delivery |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5476996A (en) | 1988-06-14 | 1995-12-19 | Lidak Pharmaceuticals | Human immune system in non-human animal |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| DK0710719T3 (da) | 1990-01-12 | 2007-07-09 | Amgen Fremont Inc | Frembringelse af xenogene antistoffer |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| EP0585287B1 (fr) | 1990-07-10 | 1999-10-13 | Cambridge Antibody Technology Limited | Methode de production de chainons de paires de liaison specifique |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| US5789650A (en) | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5814318A (en) | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5877397A (en) | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5874299A (en) | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
| WO1993012227A1 (fr) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Animaux transgeniques non humains capables de produire des anticorps heterologues |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| EP0814159B1 (fr) | 1990-08-29 | 2005-07-27 | GenPharm International, Inc. | Souris transgéniques capables de produire des anticorps hétérologues |
| DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
| CA2105300C (fr) | 1991-03-01 | 2008-12-23 | Robert C. Ladner | Procede pour le developpement de mini-proteines fixatrices |
| PT100379B (pt) | 1991-04-10 | 1999-01-29 | Scripps Research Inst | Bibliotecas de receptores heterodimericos usando fagomideos |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| WO1993006213A1 (fr) | 1991-09-23 | 1993-04-01 | Medical Research Council | Production d'anticorps chimeriques - une approche combinatoire |
| WO1993011161A1 (fr) | 1991-11-25 | 1993-06-10 | Enzon, Inc. | Proteines multivalentes de fixation aux antigenes |
| EP0640094A1 (fr) | 1992-04-24 | 1995-03-01 | The Board Of Regents, The University Of Texas System | Production recombinante de domaines semblables a l'immunoglobuline dans des cellules procaryotes |
| WO1994013804A1 (fr) | 1992-12-04 | 1994-06-23 | Medical Research Council | Proteines de liaison multivalentes et multispecifiques, leur fabrication et leur utilisation |
| EP0754225A4 (fr) | 1993-04-26 | 2001-01-31 | Genpharm Int | Animaux transgeniques capables de produire des anticorps heterologues |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| FR2734739B1 (fr) | 1995-06-01 | 1997-07-11 | Gec Alsthom Stein Ind | Dispositif de surveillance d'un broyeur a boulets |
| TW311927B (fr) | 1995-07-11 | 1997-08-01 | Minnesota Mining & Mfg | |
| EP0795743A3 (fr) | 1996-03-15 | 1998-02-25 | Japan Tobacco Inc. | Procédé et appareil de mesure de l'humidité dans l'infrarouge |
| US5839430A (en) | 1996-04-26 | 1998-11-24 | Cama; Joseph | Combination inhaler and peak flow rate meter |
| WO1998023289A1 (fr) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | Modulation de la fixation de l'igg au fcrn |
| US6277375B1 (en) * | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| WO1998050431A2 (fr) | 1997-05-02 | 1998-11-12 | Genentech, Inc. | Procede de preparation d'anticorps multispecifiques presentant des composants heteromultimeres |
| US6358058B1 (en) | 1998-01-30 | 2002-03-19 | 1263152 Ontario Inc. | Aerosol dispensing inhaler training device |
| WO2000034784A1 (fr) | 1998-12-10 | 2000-06-15 | Phylos, Inc. | Echaffaudages de proteines pour des mimes d'anticorps et autres proteines de liaison |
| EP1792991A1 (fr) | 1999-08-24 | 2007-06-06 | Medarex, Inc. | Anticorps humains contre CTLA-4 et leur utilisation |
| ES2295228T3 (es) | 2000-11-30 | 2008-04-16 | Medarex, Inc. | Roedores transcromosomicos transgenicos para la preparacion de anticuerpos humanos. |
| AU2002256371B2 (en) | 2001-04-26 | 2008-01-10 | Amgen Mountain View Inc. | Combinatorial libraries of monomer domains |
| US20030157561A1 (en) | 2001-11-19 | 2003-08-21 | Kolkman Joost A. | Combinatorial libraries of monomer domains |
| KR100913714B1 (ko) | 2001-11-08 | 2009-08-24 | 패시트 바이오테크 코포레이션 | Ｉｇｇ 항체의 안정한 액상 약학 제형물 |
| AU2003234439A1 (en) | 2002-05-07 | 2003-11-11 | Control Delivery Systems, Inc. | Processes for forming a drug delivery device |
| WO2004045507A2 (fr) * | 2002-11-15 | 2004-06-03 | Centocor, Inc. | Utilisations anti-angiogeniques d'antagonistes de il-6 |
| US7968690B2 (en) | 2003-12-23 | 2011-06-28 | Rinat Neuroscience Corp. | Agonist anti-trkC antibodies and methods using same |
| EP1776384B1 (fr) | 2004-08-04 | 2013-06-05 | Mentrik Biotech, LLC | Regions fc de variants |
| JP2008511337A (ja) | 2004-09-02 | 2008-04-17 | ジェネンテック・インコーポレーテッド | ヘテロ多量体分子 |
| US8802820B2 (en) | 2004-11-12 | 2014-08-12 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP1966244B1 (fr) | 2005-12-30 | 2012-03-21 | Merck Patent GmbH | Anticorps contre l'interleukine 6 empechant la liaison de l'il6 et de l'il-6ralpha a gp130 |
| JP2009529339A (ja) | 2006-03-13 | 2009-08-20 | アブリンクス エン．ヴェー． | Ｉｌ−６を標的とするアミノ酸配列およびそれを含みｉｌ−６介在シグナル伝達に関連する疾患および疾病を治療するポリペプチド |
| EP2021463B1 (fr) | 2006-05-19 | 2016-11-23 | Alder Biopharmaceuticals, Inc. | Procédé de culture permettant d'obtenir une population clonée de lymphocytes b spécifiques d'antigène |
| SI2164514T1 (sl) | 2007-05-21 | 2017-04-26 | Alderbio Holdings Llc | Protitelesa proti IL-6 in njihova uporaba |
| EP3124044A1 (fr) | 2007-09-14 | 2017-02-01 | Sanofi Pasteur Biologics, LLC | Compositions pharmaceutiques contenant des anatoxines a et b de clostridium difficile |
| WO2009070243A2 (fr) | 2007-11-21 | 2009-06-04 | Amgen Inc. | Agents et épitopes de liaison à wise |
| US20100187601A1 (en) | 2007-12-12 | 2010-07-29 | Fujio Masuoka | Semiconductor device |
| EP2249809A1 (fr) | 2008-01-15 | 2010-11-17 | Abbott GmbH & Co. KG | Composition de protéine pulvérisée et procédés de fabrication de celle-ci |
| EP2837388A1 (fr) | 2008-08-05 | 2015-02-18 | Novartis AG | Compositions et procédés pour anticorps ciblant une protéine C5 de complément |
| ES2395231T3 (es) | 2008-09-12 | 2013-02-11 | Kdf Co., Ltd. | Dispositivo de proyección de agua en forma de surtidor |
| WO2010039750A2 (fr) | 2008-10-01 | 2010-04-08 | Monsanto Technology Llc | Plantes transgéniques possédant des caractères agronomiques supérieurs |
| US8992920B2 (en) | 2008-11-25 | 2015-03-31 | Alderbio Holdings Llc | Anti-IL-6 antibodies for the treatment of arthritis |
| BRPI0921319A2 (pt) | 2008-11-26 | 2018-10-16 | Glaxo Group Ltd | composição, método para dispensação de uma composição, e para tratar, prevenir ou diagnosticar uma condição ocular, e, processo para produzir uma composição farmacêutica |
| SG2014007637A (en) | 2009-01-29 | 2014-03-28 | Medimmune Llc | Human anti-il-6 antibodies with extended in vivo half-life and their use in treatment of oncology, autoimmune diseases and inflammatory diseases |
| JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
| AU2011277999A1 (en) | 2010-07-12 | 2013-01-10 | Covx Technologies Ireland Limited | Multifunctional Antibody Conjugates |
| CN104428315B (zh) | 2012-07-13 | 2017-09-29 | 罗氏格黎卡特股份公司 | 双特异性抗‑vegf/抗‑ang‑2抗体及其在治疗眼血管疾病中的应用 |
| BR112015008186A2 (pt) | 2012-10-25 | 2017-09-19 | Medimmune Llc | formulação de um anticorpo estável e de baixa viscosidade |
| SG11201502876RA (en) * | 2012-11-08 | 2015-06-29 | Eleven Biotherapeutics Inc | Il-6 antagonists and uses thereof |
| JP2016531901A (ja) | 2013-07-12 | 2016-10-13 | オプソテック コーポレイションＯｐｈｔｈｏｔｅｃｈ Ｃｏｒｐｏｒａｔｉｏｎ | 眼科症状を処置するまたは予防するための方法 |
| WO2016073894A1 (fr) | 2014-11-07 | 2016-05-12 | Eleven Biotherapeutics, Inc. | Agents thérapeutiques avec une rétention oculaire accrue |
-
2015
- 2015-11-06 HU HUE15797538A patent/HUE046181T2/hu unknown
- 2015-11-06 PT PT157975384T patent/PT3215530T/pt unknown
- 2015-11-06 BR BR112017008672-7A patent/BR112017008672A2/pt active Search and Examination
- 2015-11-06 MY MYPI2017000609A patent/MY185114A/en unknown
- 2015-11-06 SG SG10202103420PA patent/SG10202103420PA/en unknown
- 2015-11-06 NZ NZ731090A patent/NZ731090A/en unknown
- 2015-11-06 DK DK15797538T patent/DK3215530T3/da active
- 2015-11-06 IL IL251858A patent/IL251858B/en unknown
- 2015-11-06 PL PL15797538T patent/PL3215530T3/pl unknown
- 2015-11-06 KR KR1020177014412A patent/KR102636726B1/ko active IP Right Grant
- 2015-11-06 JP JP2017543332A patent/JP6594438B2/ja active Active
- 2015-11-06 US US15/524,727 patent/US11142571B2/en active Active
- 2015-11-06 SI SI201530995T patent/SI3215530T1/sl unknown
- 2015-11-06 MA MA051554A patent/MA51554A/fr unknown
- 2015-11-06 ES ES15797538T patent/ES2756275T3/es active Active
- 2015-11-06 EP EP19189890.7A patent/EP3632931A1/fr active Pending
- 2015-11-06 PE PE2017000804A patent/PE20171107A1/es unknown
- 2015-11-06 EA EA201791005A patent/EA035199B1/ru not_active IP Right Cessation
- 2015-11-06 MX MX2017005992A patent/MX2017005992A/es unknown
- 2015-11-06 AU AU2015342882A patent/AU2015342882B2/en active Active
- 2015-11-06 SG SG11201703574VA patent/SG11201703574VA/en unknown
- 2015-11-06 KR KR1020247004699A patent/KR20240023450A/ko not_active Application Discontinuation
- 2015-11-06 EP EP15797538.4A patent/EP3215530B9/fr active Active
- 2015-11-06 UA UAA201705592A patent/UA122673C2/uk unknown
- 2015-11-06 EP EP23189385.0A patent/EP4268843A3/fr active Pending
- 2015-11-06 RS RS20191447A patent/RS59805B1/sr unknown
- 2015-11-06 WO PCT/US2015/059532 patent/WO2016073890A1/fr active Application Filing
- 2015-11-06 CR CR20170231A patent/CR20170231A/es unknown
- 2015-11-06 CN CN201580065652.6A patent/CN107249631B/zh active Active
- 2015-11-06 CA CA2965689A patent/CA2965689C/fr active Active
-
2017
- 2017-04-28 ZA ZA201702985A patent/ZA201702985B/en unknown
- 2017-05-02 PH PH12017500809A patent/PH12017500809A1/en unknown
- 2017-05-03 SA SA517381458A patent/SA517381458B1/ar unknown
- 2017-05-05 CL CL2017001135A patent/CL2017001135A1/es unknown
- 2017-05-08 MX MX2021008663A patent/MX2021008663A/es unknown
- 2017-05-30 CO CONC2017/0005404A patent/CO2017005404A2/es unknown
-
2018
- 2018-03-10 HK HK18103370.4A patent/HK1244008A1/zh unknown
-
2019
- 2019-10-25 HR HRP20191945TT patent/HRP20191945T1/hr unknown
-
2021
- 2021-09-13 US US17/473,696 patent/US20220169719A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FR21C1030I2 (fr) | Conjugué anticorps anti-her2-médicament | |
| KR102355950B9 (ko) | Tigit에 대한 항체 | |
| MA45004A (fr) | Anticorps spécifiques anti-wt1-hla | |
| DK3344654T3 (da) | Anti-lag-3-antistoffer | |
| MA47472A (fr) | Anticorps | |
| MA53297A (fr) | Anticorps anti-icos | |
| MA42626A (fr) | Nouveaux anticorps anti-pd-1 | |
| DK3556777T3 (da) | Multispecifikke antistofkonstrukter | |
| DK3126395T3 (da) | Multispecifikke antistoffer | |
| DK3191517T3 (da) | Krydsreaktive siglec-antistoffer | |
| DK3350218T3 (da) | Polyomavirus-neutraliserende antistoffer | |
| MA51554A (fr) | Anticorps il-6 améliorés | |
| CL2016001742A1 (es) | Anticuerpos anti-baff novedosos | |
| DK3164414T3 (da) | Antistoffer for IL-15 | |
| DK3250593T3 (da) | Anti-transthyretin-antistoffer | |
| MA42843A (fr) | Anticorps anti-cd115 | |
| DK3174483T3 (da) | Hyporørkonstruktion | |
| DK3099791T3 (da) | Protein | |
| DK3092003T3 (da) | Hidtil ukendt anti-netrin-1-antistof | |
| DK3154587T3 (da) | Konjugater omfattende et anti-egfr1-antistof | |
| DK3484921T3 (da) | Anti-IL-22R antistoffer | |
| DK3099793T3 (da) | Protein | |
| DE112015005590A5 (de) | Dosierpumpe | |
| MA43869A (fr) | Anticorps anti-myl9 | |
| FI20145330A (fi) | Immunomääritys |